Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
Both companies are approaching milestones that could light a fire under their stocks.
Overview
Given that the beginning of 2027 is now less than four months away, it wouldn't be wrong to begin positioning your portfolio for the coming year.
To this end, here's a closer look at two pharmaceutical stocks, each with a handful of developments and/or milestones already lined up that could be -- and should be -- bullish.
Details
When CRISPR Therapeutics (NASDAQ: CRSP) first won FDA approval for its gene-editing sickle cell disease treatment Casgevy back in late 2023, it was seemingly ready to launch with marketing partner Vertex Pharmaceuticals. Now, nearly three years later, there's still minimal Casgevy revenue being generated, and, technically, no reported generally accepted accounting principles (GAAP) revenue from drug sales.
Source
Originally published at www.fool.com.